AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01547416
Drug: epidural 250mL of 0.2% ropivacaine and 2 μg/mL of fentanyl, 5 mL/hr continuous infusion and 0.5 mL bolus dose
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Before the induction of anesthesia, epidural catheter was inserted in group GE at T8/9, T9/10, or T10/11 interspinous space with a 17-gauge Tuohy needle in lateral decubitus position and advanced 5 cm cephalad. .~Epidural analgesia was maintained using the patient-controlled analgesia technique containing 250 mL of 0.2% ropivacaine and 2 μg/mL fentanyl with setting of 5 mL/hr for continuous infusion and 0.5 mL of bolus dose. Lockout time was set to 15 min.~General anesthesia was induced with 2 mg/kg of propofol and 50 mg of rocuronium. After tracheal intubation, anesthesia was maintained with sevoflurane. All the patients were ventilated with controlled mode of 8 mL/kg of ideal body weight and respiratory rate was adjusted to maintain end-tidal carbon dioxide between 35-40 mmHg.
Trial: NCT01266213
Drug: Fulvestrant plus Goserelin
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fulvestrant s.c. plus Goserelin s.c.
Trial: NCT01266213
Drug: Anastrozole plus Goserelin
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anastrozole 1 mg p.o. plus Goserelin s.c.
Trial: NCT01266213
Drug: Goserelin
RxNorm normalized name: Goserelin
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Goserelin s.c.
Trial: NCT02679911
Drug: Loceryl NL
RxNorm normalized name: glyceryl
DrugBank: Glyceryl monostearate (DB11250)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical over the entire toenail plate of all affected toenails, once weekly in the evening (at bed time) after filing down the affected toenails.
Trial: NCT02679911
Drug: Ciclopirox NL
RxNorm normalized name: Ciclopirox
DrugBank: Ciclopirox (DB01188)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical over the entire toenail plate of all affected toenails and surrounding skin, once daily in the evening (at bed time) after removing the free toenail edge and diseased toenails if needed
Trial: NCT00655564
Drug: Alefacept
RxNorm normalized name: Alefacept
DrugBank: Alefacept (DB00092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alefacept's FDA indication is for the treatment of adult subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy. The approved dosing regimen is 15mg once weekly as an intramuscular injection or 7.5mg given once weekly as an intravenous bolus. The recommended regimen is a course of 12 weeks.~Alefacept is supplied as a lyophilized powder. Alefacept contains LFA3-IgG1 Fusion Protein and excipient materials (citrate, glycine and sucrose).
Trial: NCT00858871
Drug: Brivanib
RxNorm normalized name: Brivanib
DrugBank: Brivanib (DB11958)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 800 mg, Once Daily, Until disease progression or unacceptable toxicity
Trial: NCT00858871
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsules, Oral, 800 mg, twice daily, Until disease progression or unacceptable toxicity
Trial: NCT01941446
Drug: Eravacyline, Moxifloxacin, and placebo
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02617550
Drug: Vericiguat (BAY1021189)
RxNorm normalized name: Vericiguat
DrugBank: Vericiguat (DB15456)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Vericiguat up-titration from 2.5 mg to 10 mg in an interval of 14 +/- 3 days: 2.5 mg vericiguat for 14 +/-3 days given as 2 x 1.25 mg tablets followed by 5 mg vericiguat for 14 +/-3 days given as 1 x 5 mg tablet followed by 10 mg vericiguat for 14 +/-3 days given as 2 x 5 mg tablets
Trial: NCT02617550
Drug: Nitroglycerin
RxNorm normalized name: Nitroglycerin
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg nitroglycerin spray administered at 2.5 hours before treatment (vericiguat \[trough\] or placebo) on day 12, day 26 and day 40 at 4 hours after treatment (vericiguat \[peak\] or placebo) on day 13, day 27 and day 41
Trial: NCT03346122
Drug: JNJ-64991524 Dose Level 1
RxNorm normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive JNJ-64991524 at a Dose Level 1 in SAD Part 1 of study.
Trial: NCT03346122
Drug: JNJ-64991524 Dose Level 2
RxNorm normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive JNJ-64991524 at a Dose Level 2 in SAD Part 1 of study.
Trial: NCT03346122
Drug: JNJ-64991524 Dose Level 3
RxNorm normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive JNJ-64991524 at a Dose Level 3 in SAD Part 1 of study.
Trial: NCT03346122
Drug: JNJ-64991524 Dose Level 4
RxNorm normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive JNJ-64991524 at a Dose Level 4 in SAD Part 1 of study.
Trial: NCT03346122
Drug: JNJ-64991524 Dose Level 5
RxNorm normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive JNJ-64991524 at a dose of Dose Level 5 in SAD Part 1 of study.
Trial: NCT03346122
Drug: JNJ-64991524 Dose Level 6
RxNorm normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive JNJ-64991524 at a Dose Level 6 in SAD Part 1 and MAD part 2 of study.
Trial: NCT03346122
Drug: JNJ-64991524 Dose Level 7
RxNorm normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive JNJ-64991524 at a dose of Dose Level 7 in MAD Part 2 of study for 14 days.
Trial: NCT03346122
Drug: JNJ-64991524 Dose Level 8
RxNorm normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive JNJ-64991524 at a Dose Level 8 in MAD Part 2 of study for 14 days.
Trial: NCT03346122
Drug: JNJ-64991524 Dose Level 9
RxNorm normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive JNJ-64991524 at a Dose Level 9 in MAD Part 2 of study for 14 days.
Trial: NCT00494572
Drug: Montelukast
RxNorm normalized name: Montelukast
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg rapid dissolving granule in sterile water orally once
Trial: NCT00003268
Drug: amifostine trihydrate
RxNorm normalized name: Amifostine
DrugBank: Amifostine (DB01143)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003268
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003268
Drug: idarubicin
RxNorm normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04001569
Drug: AZD8186 in combination with paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Phase 1b is planned for a 4-stage dose level and the traditional 3+3 design is applied. The RP2D will be determined based on the MTD and toxicity profiles.~In phase 2 part, RP2D from the phase 1b part will be applied.~* AZD8186 ( )mg po bid, 5 days on, 2 days off~* Paclitaxel ( )mg/m² on D1,8,15 every 4 weeks
Trial: NCT04213898
Drug: SHR-1210+Albumin-bound paclitaxel + epirubicin
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neoadjuvant therapy：SHR-1210, 200mg,iv, q3w, for 6 cycles; Albumin-bound paclitaxel: 125 mg/m2, iv, d1, d8, and d15, 21 days as a cycle, for 6 cycles; Epirubicin: 75mg / m2, iv, d1, 21 days as a cycle, for 6 cycles; The surgery was performed 3-4 weeks after the completion of neoadjuvant chemotherapy.
Trial: NCT01589432
Drug: ABT-639
RxNorm normalized name: ABT-639
DrugBank: ABT-639 (DB15055)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two 50 mg oral capsules
Trial: NCT01589432
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3mg/kg infusion over 30 minutes
Trial: NCT00095758
Drug: Antidepressant + Aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Antidepressant Caps/Tablets Aripiprazole Tablets, Oral, 2-20 mg Aripiprazole, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.
Trial: NCT03945981
Drug: Dolutegravir + Lamivudine FDC
RxNorm normalized name: DOLUTEGRAVIR/LAMIVUDINE
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dolutegravir + Lamivudine FDC is available as white oval film-coated tablets which are packed in high density polyethylene (HDPE) bottles with induction seals and child-resistant closures. Each 60 milliliter (mL) bottle contains 30 tablets
Trial: NCT00758628
Drug: Blink
RxNorm normalized name: Blink Tears
DrugBank: Polyethylene glycol 400 (DB11077)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blink BID for 3 months
Trial: NCT01660412
Drug: ph Altered first
RxNorm normalized name: PH-284
DrugBank: PH-284 (DB05452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the first injection, Sodium Bicarbonate will be compounded with Tc-99m SC, to raise the pH up to \~7.40. For the second injection, the standard of care will be given, and randomly after that either standard of care, or pH altered will be given.
Trial: NCT00665600
Drug: Levalbuterol HCl
RxNorm normalized name: levalbuterol HCl
DrugBank: Levosalbutamol (DB13139)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levalbuterol 0.63 TID
Trial: NCT00665600
Drug: Levalbuterol HCl
RxNorm normalized name: levalbuterol HCl
DrugBank: Levosalbutamol (DB13139)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levabuterol 1.25 mg TID
Trial: NCT00665600
Drug: Albuterol Sulfate
RxNorm normalized name: Albuterol Sulfate
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Racemic albuterol 2.5 mg TID
Trial: NCT03118128
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin 850 mg PO three times a day plus prednisone in one 7-days cycle as pre-treatment and during the 28 days induction remission treatment, consolidation therapy and maintenance
Trial: NCT00590954
Drug: Perifosine
RxNorm normalized name: Perifosine
DrugBank: Perifosine (DB06641)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing will be continuous, and for the purpose of this trial a cycle will be defined as 28 days. Perifosine will be given as a 600 mg loading dose on day 1. The loading dose will be divided into 4 equal doses of 150 mg each. The first 3 doses should be given with food in the adult day hospital to allow intravenous antiemetic prophylaxis, and 4th dose at bedtime at home. The interval between doses of perifosine should be no less than 4 hours. On day 2, patients will start the maintenance dose of 100 mg daily at bedtime at home.~In addition to baseline serum, all patients will have weekly serum drawn during weeks 2-4.
Trial: NCT03551210
Drug: Nemonoxacin
RxNorm normalized name: nemonoxacin
DrugBank: Nemonoxacin (DB06600)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for infusion, 500 mg (250 ml)
Trial: NCT03551210
Drug: Nemonoxacin
RxNorm normalized name: nemonoxacin
DrugBank: Nemonoxacin (DB06600)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, 250 mg
Trial: NCT03551210
Drug: Tavanic
RxNorm normalized name: Cassia javanica whole extract
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Solution for infusion, 500 mg (100 ml)
Trial: NCT03551210
Drug: Tavanic
RxNorm normalized name: Cassia javanica whole extract
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Film coated tablets (each tablet is placed into a capsule shell (overencapsulated) for blinding purposes), 250 mg
Trial: NCT00001249
Drug: Yttrium-90 radiolabeled anti-Tac antibody
RxNorm normalized name: yttrium
DrugBank: Yttrium Y-90 (DB13076)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01331148
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10,000 IU/caplet, patients receiving 240,000 IU to 600,000 IU cumulative Vitamin D dose based on weight.
Trial: NCT00003217
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003217
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003217
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002510
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002510
Drug: mesna
RxNorm normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01527552
Drug: biphasic insulin aspart 50
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A single dose of each formulation administered subcutaneously (s.c., under the skin) on 2 dosing visits separated by a wash-out period of 6-12 days
Trial: NCT02398552
Drug: Sunitinib
RxNorm normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: altenative schedules of sunitinib as first line therapy in metastatic renal cell carcinoma patients.
Trial: NCT04380857
Drug: Dexamethasone ophthalmic insert 0.4 mg
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intracanalicular dexamethasone insert
Trial: NCT04132557
Drug: Methylphenidate
RxNorm normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from three United States (US) health care databases and one US electronic health record database.
Trial: NCT04132557
Drug: Lisdexamfetamine
RxNorm normalized name: Lisdexamfetamine
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lisdexamfetamine is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from three US health care databases and one US electronic health record database.
Trial: NCT04132557
Drug: Atomoxetine
RxNorm normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atomoxetine is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from on three US health care databases and one US electronic health record database.
Trial: NCT04132557
Drug: Amphetamine
RxNorm normalized name: Amphetamine
DrugBank: Amphetamine (DB00182)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amphetamine is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from on three US health care databases and one US electronic health record database.
Trial: NCT04132557
Drug: Dextroamphetamine
RxNorm normalized name: Dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextroamphetamine is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from on three US health care databases and one US electronic health record database.
Trial: NCT00514267
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT00514267
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT00973791
Drug: Six percent hydroxyethyl starch
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyethyl starch (6%) was given before or after spinal anesthesia in cesarean section
Trial: NCT04734405
Drug: Fluconazole 150 mg
RxNorm normalized name: fluconazole 150 MG
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole capsule
Trial: NCT00222469
Drug: bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10mg/kg IV on Day 1 Q 2 weeks
Trial: NCT00222469
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000mg/m2 as fixed-rate infusion at 10mg/m2/min on Day 1 and Q 2 weeks.
Trial: NCT00222469
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100mg/m2 on Day 2 and Q 2 weeks.
Trial: NCT01888497
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250 mg, oral, prior to bedtime on the night before performance testing
Trial: NCT01888497
Drug: Diphenhydramine citrate
RxNorm normalized name: Diphenhydramine Citrate
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 76 mg, oral, prior to bedtime on the night before performance testing
Trial: NCT01888497
Drug: Triazolam
RxNorm normalized name: Triazolam
DrugBank: Triazolam (DB00897)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5 mg, oral, prior to bedtime on the night before performance testing
Trial: NCT03240575
Drug: Tiotropium
RxNorm normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed Dose Combination
Trial: NCT03240575
Drug: Olodaterol
RxNorm normalized name: Olodaterol
DrugBank: Olodaterol (DB09080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fixed Dose Combination
Trial: NCT03240575
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fixed Dose Combination
Trial: NCT03240575
Drug: Salmeterol
RxNorm normalized name: Salmeterol
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fixed Dose Combination
Trial: NCT04561076
Drug: HLX70
RxNorm normalized name: HLX70
DrugBank: HLX70 (DB16509)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose, intravenous infusion
Trial: NCT04223076
Drug: Chlorhexidine 0.2%, Corsodyl
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparison of Corsodyl and Curasept
Trial: NCT04223076
Drug: Chlorhexidine 0.2%, Curasept
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine 0.2% mouthwash with an Anti Discoloring System (ADS)
Trial: NCT03568942
Drug: Gepotidacin
RxNorm normalized name: gepotidacin
DrugBank: Gepotidacin (DB12134)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gepotidacin tablets will be available at a dose strength of 750 mg. Tablets will be administered BID with water after consumption of food.
Trial: NCT00983554
Drug: Anastrazole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arimidex 1mg daily
Trial: NCT00983554
Drug: Dutasteride
RxNorm normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Avodart 2.5mg daily
Trial: NCT00983554
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acyline 300 µg/kg subcutaneous injections every 2 weeks
Trial: NCT01076985
Drug: Lopinavir/ritonavir (Kaletra)
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lopinavir/ritonavir (LPV/r) evaluated separately in patients who were naive to previous antiretroviral treatment and those who were not.
Trial: NCT01422499
Drug: zolinza/vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: orally once per day (suspension of 50mg/ml or capsules of 100 mg vorinostat); starting dose will be 180 mg/m²/d; escalated with increments of 50 mg/m²/d every two weeks until dose limiting toxicity (grade 3 or 4 toxicity according to CTC) occurs or up to a maximum dose of 580 mg/m²/d; This dose will then be applied for 3 months. Patients without progression at first response evaluation will continue treatment for a maximum of 9 months.
Trial: NCT00202904
Drug: ezetimibe
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ezetimibe 10 mg tablets, one tablet taken daily with atorvastatin 10 mg daily for 6 weeks
Trial: NCT00733720
Drug: Suboxone
RxNorm normalized name: Suboxone
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 4/1mg, 8/2mg 16/4mg
Trial: NCT01674686
Drug: Sarpogrelate
RxNorm normalized name: Sarpogrelate
DrugBank: Sarpogrelate (DB12163)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarpogrelate 100mg twice a day
Trial: NCT01674686
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80mg daily
Trial: NCT03391973
Drug: Pembrolizumab Injection
RxNorm normalized name: pembrolizumab Injection
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab 200 mg will be administered as a 30 minute IV infusion Q3W.
Trial: NCT03692546
Drug: Liposomal bupivacaine (LB)
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Addition of LB solution to soft tissue surgical field block to a standard interscalene block procedure